New Drug Hits Schistosome Parasite at Every Life Stage

Schistosomiasis is a tropical illness caused by tiny blood flukes called Schistosoma. Over a quarter of a billion people carry the parasite worldwide. Patients today rely on a single medicine, praziquantel, which was discovered half a century ago. Researchers need fresh options because resistance can grow and elimination goals become tougher. The disease touches many phases of life, so a treatment that works across all stages is vital.

The experimental compound, M5493, activates a parasite’s transient receptor potential channel. This target differs from the one used by praziquantel, helping to sidestep existing resistance. Because the original form doesn’t absorb well, scientists converted it into a prodrug that can enter the body more efficiently. The modified version still retains strong activity against the worm.

In laboratory mice, the drug performed well at very low doses—just 5 milligrams per kilogram of body weight. Mice infected with Schistosoma mansoni were cleared after a single dose. Unlike the benzodiazepine meclonazepam, which also targets the same channel but causes drowsiness, M5493 does not bind to GABAA receptors. This means users avoid the sedative effects seen with other agents.

If the findings translate to humans, the compound could become a one‑dose cure that tackles all parasite stages. Its wide‑range effectiveness can treat current infections and stop the parasite from spreading. The absence of sedation makes it more comfortable for patients, and the unique target reduces the risk of cross‑resistance. In short, M5493 appears to be a promising step toward ending schistosomiasis.